3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Colorectal Neoplasms
28
Rectal Neoplasms
25
Stomach Neoplasms
24
Colonic Neoplasms
13
Neoplasms
3
Neoplasm Metastasis
3
Adenocarcinoma
3
Gastrointestinal Neoplasms
2
Waldenstrom Macroglobulinemia
1
Turcot syndrome
1
Recurrence
1
Rcctal Cancer
1
Peripheral Nervous System Diseases
1
Metastatic HER2 Positive Gastroesophageal Junction Cancer
1
Locally Advanced Rectal Cancer (LARC)
1
Locally Advanced Rectal Cancer
1
Locally Advanced Gastric Cancer
1
Locally Advanced Colorectal Cancer
1
Intestinal Neoplasms
1
HER2-positive Locally Advanced Resectable Gastric Cancer
1
HER2-positive Colorectal Cancer
1
Gastrointestinal Diseases
1
Gastric Cancer Stage
1
Gastric Adenocarcinoma
1
Esophageal Neoplasms
1
Digestive System Diseases
1
Colorectal Cancer Metastatic
1
Colonic Diseases
1
Carcinoma
1
Adenocarcinoma of the Lower Rectum
1
Interventions
pembrolizumab
10
Nivolumab
9
Ipilimumab
4
avelumab
3
Neoadjuvant Therapy
3
toripalimab
2
sintilimab
2
durvalumab
2
atezolizumab
2
Specimen Handling
2
Immune Checkpoint Inhibitors
2
Celecoxib
2
tislelizumab
1
spartalizumab
1
relatlimab
1
regorafenib
1
fludarabine phosphate
1
fludarabine
1
dostarlimab
1
denileukin diftitox
1
danvatirsen
1
camrelizumab
1
XELOX
1
Taxes
1
Surgical Procedures, Operative
1
Radiation Dose Hypofractionation
1
Paclitaxel
1
Oxaliplatin
1
Megestrol Acetate
1
Medroxyprogesterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Turcot syndrome
×
XELOX
×
Clear all
NCT07266025
2026-01-27
CATALIS
Shanghai Zhongshan Hospital
Phase 2
Not yet recruiting
30 enrolled